REMS Program Medications as Extreme Severity Evidence in PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 9 min read

REMS (Risk Evaluation and Mitigation Strategies) medications require FDA-mandated safety programs beyond standard prescribing. When a PI plaintiff receives a REMS medication, it documents that their condition was severe enough to warrant a drug so dangerous the FDA requires special oversight. Learn how to use REMS status as extreme severity evidence.

A REMS (Risk Evaluation and Mitigation Strategies) program is an FDA-mandated safety system required for medications whose risks are so serious that the FDA determined standard prescribing safeguards are insufficient. When a personal injury plaintiff's pharmacy record includes a REMS medication, it is among the strongest objective evidence of extreme injury severity available. The prescriber determined that the plaintiff's condition was so severe that it justified a medication requiring federal safety program enrollment, mandatory patient agreements, specialized pharmacy certification, and ongoing monitoring -- a level of pharmacological intervention that goes far beyond routine prescribing.

• REMS programs are the FDA's highest tier of prescribing oversight, reserved for medications with the most serious risk profiles
• Only a small fraction of medications require REMS -- their presence in a plaintiff's record is exceptional and demands attention in litigation
• REMS requirements may include prescriber certification, patient enrollment in registries, mandatory laboratory monitoring, and restricted dispensing through certified pharmacies
• LienScripts identifies every REMS medication in a plaintiff's regimen and explains the program requirements and clinical significance in every MERIT (Medication Evaluation & Rationale for Injury Treatment) report
• Defense cannot minimize injury severity when the federal government requires a dedicated safety program to allow the medication to be prescribed at all

What Is a REMS Program?

The FDA can require a REMS when it determines that a medication's known or potential serious risks require safety measures beyond the standard prescribing information. A REMS is not a warning label. It is an active, ongoing safety program with mandatory requirements for prescribers, pharmacies, and often patients.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "A REMS medication is the pharmacological equivalent of heavy machinery -- it requires licensing, training, and active monitoring to operate safely. When I see a REMS medication in a plaintiff's pharmacy record, it tells me the prescriber went to extraordinary lengths because the injury demanded extraordinary treatment. The FDA does not impose REMS requirements on medications it considers manageable through normal prescribing."

REMS programs can include any or all of the following elements:

• Medication Guide -- patient-facing information that must be dispensed with every fill
• Communication Plan -- targeted education for healthcare providers
• Elements to Assure Safe Use (ETASU) -- the most restrictive component, which may require:
  • Prescriber certification and training
  • Patient enrollment in a registry
  • Pharmacy certification
  • Mandatory laboratory monitoring before and during treatment
  • Restricted dispensing (only through certified pharmacies)
  • Patient acknowledgment forms

REMS Medications Relevant to Personal Injury Cases

Extended-Release and Long-Acting Opioid Analgesics (ER/LA Opioid REMS)

The Opioid Analgesic REMS is one of the most widely applicable REMS programs in PI cases. It covers extended-release and long-acting opioid formulations including:

• OxyContin (extended-release oxycodone)
• MS Contin (extended-release morphine)
• Duragesic (fentanyl transdermal patches)
• Opana ER (extended-release oxymorphone)
• Nucynta ER (extended-release tapentadol)

When a plaintiff's pharmacy record includes an ER/LA opioid subject to the REMS, it documents that their pain was so severe and persistent that it required around-the-clock opioid management through a medication the FDA subjects to its most stringent oversight. The prescriber accepted REMS requirements -- including training obligations and patient counseling -- because the plaintiff's clinical condition demanded continuous opioid therapy.

Clozapine (Clozaril REMS)

While less common in PI cases, clozapine may appear in cases involving severe post-traumatic psychiatric conditions. Clozapine carries a REMS requiring:

• Mandatory enrollment in the Clozapine REMS Program registry
• Regular absolute neutrophil count (ANC) monitoring
• Certified pharmacy dispensing only

Its presence in a PI medication record documents psychiatric severity at the extreme end of the spectrum.

Isotretinoin (iPLEDGE REMS)

In rare PI cases involving severe scarring or dermatological injuries, isotretinoin's REMS (iPLEDGE) documents the severity of the dermatological condition:

• Monthly pregnancy testing requirements
• Mandatory patient registry enrollment
• Restricted prescribing and dispensing

Transmucosal Immediate-Release Fentanyl (TIRF REMS)

The TIRF REMS covers rapid-onset fentanyl products used for breakthrough cancer pain but occasionally seen in catastrophic injury cases with severe refractory pain:

• Actiq (fentanyl lozenge)
• Fentora (fentanyl buccal tablet)
• Abstral (fentanyl sublingual tablet)

The TIRF REMS requires prescriber enrollment, patient enrollment, and certified pharmacy dispensing. Its presence in a PI record documents pain severity at the extreme end of the clinical spectrum.

Pregabalin/Gabapentinoid Products (Under Evolving REMS)

While gabapentin and pregabalin are not currently subject to REMS, the regulatory landscape is evolving. Attorneys should monitor for any REMS requirements imposed on gabapentinoid products.

The Evidentiary Argument

The argument for REMS medications as severity evidence is the strongest version of the pharmacological severity framework:

1. The FDA -- the federal agency charged with drug safety -- determined this medication is so dangerous it requires a dedicated safety program
2. The prescriber accepted the burden of REMS compliance -- certification, monitoring, patient counseling -- because the plaintiff's condition demanded this medication
3. The patient enrolled in a federal safety program and accepted monitoring requirements because their symptoms were severe enough to justify the risk
4. The pharmacy was certified to dispense this medication, adding another layer of oversight that exists solely because of the drug's risk profile

Every participant in the prescribing chain -- FDA, prescriber, patient, pharmacy -- took extraordinary steps because the plaintiff's injury required it. That collective acceptance of extraordinary risk is powerful evidence of extraordinary severity.

Presenting REMS Evidence in Demand Packages

In a demand package, REMS medications deserve prominent treatment:

"The plaintiff's pain management regimen includes OxyContin (extended-release oxycodone), which is subject to the FDA's Risk Evaluation and Mitigation Strategies (REMS) program -- the most restrictive prescribing oversight the federal government imposes on any medication. The treating physician's decision to prescribe a REMS-regulated medication reflects a clinical determination that the plaintiff's pain from the multilevel disc herniations was so severe and persistent that it required around-the-clock opioid therapy subject to federal safety monitoring. No prescriber reaches for a REMS medication when less-regulated alternatives will suffice."

REMS in the Context of Other Severity Indicators

REMS medications sit at the apex of the pharmacological severity framework:

1. Non-controlled, non-black-box medications (lowest severity indicator)
2. Black box warning medications (significant severity)
3. DEA Schedule II controlled substances (high severity with federal tracking)
4. REMS medications (extreme severity with mandatory federal safety programs)

When a plaintiff's regimen includes a REMS medication, it anchors the severity argument at the highest possible level.

Countering Defense Arguments

"The plaintiff is on opioids, which are commonly prescribed."

Immediate-release opioids are relatively commonly prescribed. Extended-release opioids subject to REMS are not routine. The REMS requirement distinguishes these medications from standard opioid prescribing and documents a level of severity and chronicity beyond what short-acting opioids address.

"REMS is just a bureaucratic requirement."

REMS programs exist because the FDA made a science-based determination that the medication's risks are too serious for standard oversight. Characterizing this as bureaucracy minimizes the federal government's assessment of the drug's danger profile -- an assessment the prescriber accepted when choosing this medication for the plaintiff.

"The prescriber should have used non-REMS alternatives."

If non-REMS alternatives were adequate, the prescriber would have used them. The treatment record typically shows a progression through less-restricted options that proved insufficient before the REMS medication was initiated. A MERIT report from LienScripts documents this escalation pathway.

The Clinical Pearl

A REMS medication in a plaintiff's pharmacy record is not just another prescription. It is a medication the FDA determined was so dangerous it required a dedicated federal safety program, prescribed by a physician who accepted extraordinary regulatory burden, filled by a certified pharmacy, and taken by a patient who enrolled in a federal monitoring system. Every element of that chain documents extraordinary clinical severity. Attorneys who understand and present REMS status in this context communicate the extreme nature of the plaintiff's injury in terms that adjusters, mediators, and juries cannot ignore.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that identifies every REMS medication, explains the specific REMS requirements, and articulates the clinical severity implied by the prescribing decision.

Related Resources

• Black Box Warning Medications as Severity Evidence -- How FDA safety warnings prove injury severity in PI cases
• DEA Scheduling as a Pain Severity Indicator -- Using controlled substance classification to frame severity